Will Aldeyra Hit the Bull’s Eye in Dry Eye?
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) announced positive results from the Phase 3 tranquility trial, which achieved its primary endpoint of being statistically superior...
Coverage
- All
- Beauty
- Biotechnology
- Cannabis
- Communications
- Education
- Energy
- Entertainment
- Environment
- ETFs
- Finance
- Fitness
- Food and Beverage
- Healthcare
- Hospitality
- Insider Trading
- Investing Ideas
- Macro
- Market Insight
- Miscellaneous
- Power
- Real Estate
- Retail
- Sectors
- Security
- Startups
- Technologies
- Trending
- Uncategorized
Canoo Inc: In the Driver’s Seat Once Again?
Canoo Inc. (NASDAQ: GOEV), an EV start-up that aspires to be a high-tech advanced mobility company, announced the signing of a definitive agreement...
Here’s why you should watch Greenwich Lifesciences
Greenwich LifeSciences, Inc. (NASDAQ: GLSI), a clinical-stage pharmaceutical company, developing immunotherapy to prevent breast cancer recurrence in patients who previously underwent surgery, announced...
Digital World Acquisition Corp: 6 Things You Should Know
The Company Digital World Acquisition Corp. (NASDAQ: DWAC) is a blank check company that seeks to forge business combinations with FinTech, Tech, or Media...
Here’s a round-up on Veru Inc!
Positive Results from Phase 3 trial of Sabizabulin Veru, Inc. (NASDAQ: VERU) announced the publication of results from a Phase 3 study evaluating the...
Upcoming Catalyst Makes Iveric Bio a Must Watch!
Iveric Bio, Inc. ( NASDAQ: ISEE) is a clinical-stage biopharmaceutical company developing transformative therapies for retinal diseases with significant unmet needs. The Company...
7 Things You Should know about Upstart!
Upstart Holdings, Inc. (NASDAQ: UPST) is a cloud-based artificial intelligence lending platform that operates in the United States. The Company is a bridge...
Kezar Makes a Solid Comeback!
Kezar Life Sciences, Inc. (NASDAQ: KZR), a clinical-stage biotechnology company, reported positive top-line results from the Phase 2 clinical trial named MISSION, evaluating...
Here’s why Emergent BioSolutions is worth investing!
Emergent BioSolutions, Inc. (NYSE: EBS), a life sciences company is developing a portfolio of vaccines and therapeutics for urgent health threats, announced the...
